CVS Health struck a deal with dissident Glenview Capital, giving the investor four board seats. Glenview had been pushing for changes at the health-care giant and had met with former CEO Karen Lynch prior to her ouster.

CVS Health said on Monday it added four new members to its board including hedge fund Glenview Capital's chief executive Larry Robbins as part of a standstill agreement with the activist investor. Shares of CVS rose 2% to $54.

The board of directors at CVS is being expanded to 16 members to accommodate the new appointees. The other new directors are Leslie Norwalk, Guy Sansone and Doug Schulman. Glenview Capital has amassed a sizable stake in CVS stock and is agitating for change, including helping to precipitate Lynch's removal as CEO.